Summit Financial Group Inc. boosted its position in iShares NASDAQ Biotechnology Index (NASDAQ:IBB) by 161.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,845 shares of the financial services provider’s stock after acquiring an additional 6,695 shares during the quarter. Summit Financial Group Inc.’s holdings in iShares NASDAQ Biotechnology Index were worth $1,158,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of IBB. First Trust Advisors LP raised its holdings in iShares NASDAQ Biotechnology Index by 0.5% during the second quarter. First Trust Advisors LP now owns 3,426 shares of the financial services provider’s stock worth $1,062,000 after purchasing an additional 18 shares in the last quarter. Atlantic Trust Group LLC raised its holdings in iShares NASDAQ Biotechnology Index by 35.0% during the second quarter. Atlantic Trust Group LLC now owns 18,362 shares of the financial services provider’s stock worth $5,695,000 after purchasing an additional 4,757 shares in the last quarter. Eaton Vance Management raised its holdings in iShares NASDAQ Biotechnology Index by 5.1% during the second quarter. Eaton Vance Management now owns 3,105 shares of the financial services provider’s stock worth $963,000 after purchasing an additional 151 shares in the last quarter. Financial Counselors Inc. raised its holdings in iShares NASDAQ Biotechnology Index by 19.6% during the second quarter. Financial Counselors Inc. now owns 7,417 shares of the financial services provider’s stock worth $2,300,000 after purchasing an additional 1,215 shares in the last quarter. Finally, Capital Fund Management S.A. raised its holdings in iShares NASDAQ Biotechnology Index by 87.6% during the second quarter. Capital Fund Management S.A. now owns 34,517 shares of the financial services provider’s stock worth $10,703,000 after purchasing an additional 16,118 shares in the last quarter. 21.09% of the stock is currently owned by hedge funds and other institutional investors.

iShares NASDAQ Biotechnology Index (NASDAQ:IBB) traded down $1.05 during mid-day trading on Thursday, reaching $109.83. 3,637,500 shares of the company’s stock were exchanged, compared to its average volume of 3,701,600. iShares NASDAQ Biotechnology Index has a 12 month low of $88.96 and a 12 month high of $114.17. The firm has a market capitalization of $10,230.00, a PE ratio of 3.63 and a beta of 1.38.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 28th. Shareholders of record on Friday, December 22nd were issued a dividend of $0.125 per share. The ex-dividend date was Thursday, December 21st. This represents a $0.50 dividend on an annualized basis and a yield of 0.46%. This is a boost from iShares NASDAQ Biotechnology Index’s previous quarterly dividend of $0.04. iShares NASDAQ Biotechnology Index’s dividend payout ratio (DPR) is presently 2.38%.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/summit-financial-group-inc-has-1-16-million-position-in-ishares-nasdaq-biotechnology-index-ibb/1794327.html.

About iShares NASDAQ Biotechnology Index

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares NASDAQ Biotechnology Index (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares NASDAQ Biotechnology Index (NASDAQ:IBB)

Receive News & Ratings for iShares NASDAQ Biotechnology Index Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares NASDAQ Biotechnology Index and related companies with Analyst Ratings Network's FREE daily email newsletter.